Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Pretzel Therapeutics logo — Welcome to a new era in mitochondrial therapeutics

Pretzel Therapeutics

Welcome to a new era in mitochondrial therapeutics

Founded 2019 United States Boston, United States 46 employees Series A Total: $72.50M Biotechnology, Health and Wellness +1

General Information

Company Name Pretzel Therapeutics
Founded Year 2019
Location United States Boston, United States
Employees 46
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Pretzel Therapeutics. To contact Pretzel Therapeutics, visit pretzeltx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pretzel Therapeutics compare?

A PDF of Pretzel Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pretzel Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pretzel Therapeutics

Pretzel Therapeutics is a biotechnology and pharmaceutical startup established in 2019, headquartered in the United States. With the slogan "Welcome to a new era in mitochondrial therapeutics," Pretzel Therapeutics is on a mission to develop groundbreaking therapies to reverse mitochondrial dysfunction. Mitochondria, the energy-converting cellular organelles, are implicated in over 50 diseases, including rare genetic conditions and aging-related disorders. The startup aims to target the genetic drivers of mitochondrial dysfunction, potentially offering effective treatment options across a wide range of diseases that currently lack meaningful solutions. The company recently secured a significant $72.50M Series A investment on 12 September 2022. The investment was led by a notable group of investors including Arch Venture Partners, GV, HealthCap, Invus, Angelini Ventures, Eir Ventures, GU Ventures, University of Cambridge Enterprise, Karolinska, and Mubadala Capital Ventures. This substantial investment reflects the confidence of prominent venture capital firms in the potential of Pretzel Therapeutics' innovative approach to address mitochondrial dysfunction. Overall, Pretzel Therapeutics is positioned at the forefront of mitochondrial therapeutics, with a promising focus on addressing crucial medical needs through its pioneering research and development efforts. With the recent major investment, the company is well-positioned to advance its mission and potentially make significant strides in the treatment of mitochondrial-related diseases.

Business keywords: mitochondrial therapeutics, mitochondrial dysfunction, mitochondrial biology, rare genetic conditions, genetic drivers, therapeutics development, cellular organelles, energy conversion, age-related disorders, mitochondrial diseases, treatment options, mechanistic understanding, mitochondrial research, biomedical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $72.50M 10
Arch Venture Partners GV HealthCap
Arch Venture Partners, GV +8
12 Sep 2022
Venture Round Undisclosed -
10 Oct 2021

Pretzel Therapeutics Alternatives & Competitors

View All Alternatives
Pretzel Therapeutics vs
Booster Therapeutics
Booster Therapeutics Germany

Pioneering proteasome therapeutics for a new approach to complex disease

7 employees
Biotechnology, Health and Wellness
Compare Pretzel Therapeutics vs Booster Therapeutics
Pretzel Therapeutics vs
Alltrna
Alltrna United States

The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potent...

Series B
49 employees
Biotechnology, Health Care
Compare Pretzel Therapeutics vs Alltrna
Pretzel Therapeutics vs
Perlara PBC
Perlara PBC

Perlara is a the first biotech PBC on a mission to codevelop drugs with highly motivated families ra...

Series A
14 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Pretzel Therapeutics

Welcome to a new era in mitochondrial therapeutics
Pretzel Therapeutics was founded in 2019.
Pretzel Therapeutics is headquartered in Boston, United States.
Pretzel Therapeutics operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on mitochondrial therapeutics, mitochondrial dysfunction, mitochondrial biology and rare genetic conditions.
Pretzel Therapeutics has approximately 46 employees.
Pretzel Therapeutics has completed 2 funding rounds, raising a total of $72.50M. The latest funding stage is Series A.
Top alternatives and competitors to Pretzel Therapeutics include Booster Therapeutics, Alltrna, Perlara PBC, Immunaeon, Dicerna Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pretzel Therapeutics and Booster Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pretzel Therapeutics, https://bouncewatch.com/company/pretzel-therapeutics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout